戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nced reactive myeloproliferative response to thrombopoietin.
2 n, soluble transferrin receptor (sCD71), and thrombopoietin.
3 pon stimulation of primary megakaryocytes by thrombopoietin.
4 es, and show altered biochemical response to thrombopoietin.
5 an CD34(+) cells cultured in the presence of thrombopoietin.
6  reduced levels of plasma erythropoietin and thrombopoietin.
7 cktail of stem cell factor, flt3 ligand, and thrombopoietin.
8 ured in the presence of stem cell factor and thrombopoietin.
9 ption factor scl and c-mpl, the receptor for thrombopoietin.
10 unction, and raised serum erythropoietin and thrombopoietin.
11 -6, stem cell factor (SCF), Flt3 ligand, and thrombopoietin.
12 cting cytokines kit ligand, flt3 ligand, and thrombopoietin.
13 two doses of 1.2 microg/kg recombinant human thrombopoietin.
14 feration of BaF3/Mpl cells in the absence of thrombopoietin.
15  and controls the proliferative responses to thrombopoietin.
16 tem-cell-derived hematopoietic cultures with thrombopoietin, a multistage cytokine.
17                                              Thrombopoietin affects nearly all aspects of platelet pr
18 ecular and cellular mechanisms through which thrombopoietin affects platelet production provide new i
19 prove response rates, as recently shown with thrombopoietin analogs.
20 lear cells were incubated in the presence of thrombopoietin and 10% plasma from either ITP patients (
21                                              Thrombopoietin and basic fibroblast growth factor are id
22  expression profiles correlated with that of thrombopoietin and found that genes whose expression ass
23 egulation occurs with the receptors for Epo, thrombopoietin and growth hormone but not with the recep
24 binant hemopoietic growth factors, including thrombopoietin and interkeukin-11, may be useful future
25 e potential of hemopoietic growth factors (, thrombopoietin and interleukin-11) to prevent or treat n
26                                    Silencing thrombopoietin and interleukin-6 abrogated thrombocytosi
27                             Plasma levels of thrombopoietin and interleukin-6 were significantly elev
28                                              Thrombopoietin and its receptor (Mpl) support survival a
29 ereas megakaryocyte progenitors treated with thrombopoietin and LY294002 showed both a G(1) and a G(2
30                  BaF3/Mpl cells treated with thrombopoietin and LY294002 were blocked in G(1), wherea
31 development of antibodies against endogenous thrombopoietin and subsequent refractory thrombocytopeni
32 gulate the expression of genes such as THPO (thrombopoietin) and ATP5B (ATP synthase, H+ transporting
33 x were reduced, while reticulated platelets, thrombopoietin, and bone marrow megakaryocyte colony-for
34 r angiogenic growth factors (angiopoietin-2, thrombopoietin, and epidermal growth factor).
35 ure containing IL-3, IL-6, stem cell factor, thrombopoietin, and Flt3 ligand induced Ccn3/Nov mRNA ov
36 ng STAT5 phosphorylation in response to IL3, thrombopoietin, and GM-CSF.
37                  Because the erythropoietin, thrombopoietin, and granulocyte colony-stimulating facto
38 topoietic cell receptors for erythropoietin, thrombopoietin, and granulocyte colony-stimulating facto
39 ter exhibited reduced proplatelet formation, thrombopoietin, and integrin signaling.
40 tly of the key regulator of megakaryopoiesis thrombopoietin, and may occur during situations of acute
41 n mice by phlebotomy or by administration of thrombopoietin, and ultrastructural analysis was perform
42 h the recent cloning and characterization of thrombopoietin, appreciation of the molecular events sur
43 being given a new spin, newer agents such as thrombopoietins are showing significant promise.
44 ifferentiation process driven by the hormone thrombopoietin by which haematopoietic progenitor cells
45 ic progenitor cells, during pre-expansion by thrombopoietin, c-kit ligand, and FLT-3 ligand, on recom
46 ved platelets derived from recombinant human thrombopoietin can provide a viable strategy to minimise
47                        We identify roles for thrombopoietin, CCL3, and direct cell-cell interactions
48 platelet and red blood cell variability, and thrombopoietin/cellular myeloproliferative leukemia viru
49 s harvested from healthy donors treated with thrombopoietin could provide larger increases in platele
50 yocytes may reduce metastasis, we found that thrombopoietin-deficient mice exhibited a 90% relative d
51 imulated hematopoiesis both in wild-type and thrombopoietin-deficient mice.
52  rapidly overgrown by a unique population of thrombopoietin-dependent blasts that express immature ma
53 NK mutants displayed augmented and sustained thrombopoietin-dependent growth and signaling.
54                               Transfusion of thrombopoietin-derived autologous platelets might provid
55 ssful search to purify and molecularly clone thrombopoietin did not begin until the oncogene v-mpl wa
56                                  Strikingly, thrombopoietin-differentiated DAMI cells, which represen
57 ation of transforming growth factor-beta1 in thrombopoietin-driven experimental myelofibrosis in mice
58  response to stem cell factor and diminished thrombopoietin-evoked Erk activation.
59                            Recombinant human thrombopoietin facilitated collection of multiple units
60 ne marrow cells grown in liquid culture with thrombopoietin failed to develop polyploid cells greater
61                           The combination of thrombopoietin, Flt3 ligand, and stem cell factor upregu
62  here that the 2 cytokines interleukin 3 and thrombopoietin have the ability to expand hematopoietic
63                              The recombinant thrombopoietins have been shown to be effective stimulat
64 ve reduced activation of Rap1 in response to thrombopoietin, IGF-1,ADP, SFLLRN, and thrombin.
65 ys with OP9 stromal cells in the presence of thrombopoietin, IL-6, and IL-11 resulted in the developm
66                                The levels of thrombopoietin, immature platelet fraction, and mean pla
67 rmined by quantification of platelet counts, thrombopoietin, immature platelet fraction, and mean pla
68 utants and platelets from patients displayed thrombopoietin-independent phosphorylation of signal tra
69 activity is necessary but not sufficient for thrombopoietin-induced cell cycle progression.
70 hosphatidylinositol 3-kinase is required for thrombopoietin-induced cell cycling in BaF3/Mpl cells an
71 R-34a expression is also up-regulated during thrombopoietin-induced differentiation of CD34(+) hemato
72 ispensable for megakaryocytopoiesis, and for thrombopoietin-induced ERK1/2 activation in primary mega
73 y increase in A-Raf or B-Raf expression, and thrombopoietin-induced ERK1/2 phosphorylation is similar
74 theless, the absence of Raf-1 does not alter thrombopoietin-induced expansion of primary megakaryocyt
75  from human haematopoietic progenitor cells, thrombopoietin-induced megakaryocytic differentiation le
76 f significant stromal fibrosis in a model of thrombopoietin-induced myelofibrosis.
77 aF3/Mpl cells and megakaryocyte progenitors, thrombopoietin-induced phosphatidylinositol 3-kinase act
78                           Here, we show that thrombopoietin induces phosphatidylinositol 3-kinase and
79 tors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high
80 tact with hECs and minimal concentrations of thrombopoietin/Kit-ligand/Flt3-ligand resulted in a 400-
81                                       Plasma thrombopoietin levels inversely correlated with platelet
82                                        Serum thrombopoietin levels overlapped in mutant vs control mi
83 yrosine kinase JAK2 and elevated circulating thrombopoietin levels.
84                                              Thrombopoietin may increase the number of hematopoietic
85                      An observed increase in thrombopoietin-mediated Akt phosphorylation in the trunc
86  illustrate an involvement for GP Ibalpha in thrombopoietin-mediated events of megakaryocyte prolifer
87 tients, resulting in diminished thrombin and thrombopoietin-mediated integrin alpha(IIb)beta(3) activ
88                                 In addition, thrombopoietin-mediated JAK2 phosphorylation was unchang
89 a/14-3-3xi/PI-3 kinase complex in regulating thrombopoietin-mediated responses.
90 unosuppression to determine whether the oral thrombopoietin mimetic eltrombopag (Promacta) can improv
91 ponse may also occur with alemtuzumab or the thrombopoietin mimetic eltrombopag in refractory AA.
92 hGH enhances the effect of a tandem dimer of thrombopoietin mimetic peptide (dTMP) on thrombopoiesis,
93 ed the efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or interme
94                               Romiplostim, a thrombopoietin mimetic, increases platelet counts in pat
95        Eltrombopag belongs to a new class of thrombopoietin-mimetic drugs that raise platelet counts
96                               Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintain
97 ated by the therapeutic effectiveness of the thrombopoietin mimetics in ITP.
98 te-macrophage colony-stimulating factor, and thrombopoietin); most have proinflammatory effects.
99 tly reported increased in vivo activities of thrombopoietin (Mpl ligand) and leptin following carbohy
100 cluding receptors for erythropoietin (EPOR), thrombopoietin (MPL), and granulocyte colony-stimulating
101 cture a small upstream open reading frame in thrombopoietin mRNA, and the resulting overproduction of
102  is a loss-of-function variant that promotes thrombopoietin/myeloproliferative leukemia virus oncogen
103  in isolated MKs increased signaling via the thrombopoietin/myeloproliferative leukemia virus oncogen
104  megakaryocytic and erythroid progenitors by thrombopoietin or erythropoietin was unaffected.
105          When HEL cells were stimulated with thrombopoietin or phorbol 12-myristate 13-acetate (PMA),
106 2%) amplification cultures with two (Flt3L + thrombopoietin) or four cytokines (Flt3L + thrombopoieti
107 megakaryocytes in the presence or absence of thrombopoietin, or the development of megakaryocyte DNA
108  to be related to marrow injury or decreased thrombopoietin production.
109 bol-13-acetate and primary megakaryocytes by thrombopoietin promotes MKL1 nuclear localization.
110 growth factor receptor-1 (F36VFGFR1) and the thrombopoietin receptor (F36VMpl) induced a sustained ex
111 d to express a conditional derivative of the thrombopoietin receptor (F36Vmpl).
112 59457 (SB), a nonpeptidyl hydrazone class of thrombopoietin receptor (Mpl) agonist, revealed toxicity
113 5R/R938Q induced spontaneous growth of Ba/F3-thrombopoietin receptor (MPL) but not of Ba/F3-human rec
114                   We have reported defective thrombopoietin receptor (Mpl) protein expression in MPD
115             Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and the erythropoietin re
116 port here that amino acid substitutions in a thrombopoietin receptor (Mpl)--containing cell growth sw
117 ombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been ap
118 ts before (n = 10) and during treatment with thrombopoietin receptor (TPO-R) agonists (n = 9).
119                  Decreased expression of the thrombopoietin receptor (TPOR or MPL) on the cell surfac
120 ns participate in the activity states of the thrombopoietin receptor (TpoR), a type 1 cytokine recept
121                                 In the human thrombopoietin receptor (TpoR), a unique amphipathic RWQ
122 l, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), being developed as a tre
123 ase 2 phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl) activation, was affec
124 genic CALR mutants specifically activate the thrombopoietin receptor (TpoR/MPL).
125 xamine the in vivo effects of eltrombopag, a thrombopoietin receptor agonist (TPO-RA), on platelet fu
126                                          The thrombopoietin receptor agonist eltrombopag has been sho
127                                     The oral thrombopoietin receptor agonist eltrombopag is approved
128                       Eltrombopag (ELT) is a thrombopoietin receptor agonist reported to decrease lab
129                                          The thrombopoietin receptor agonist romiplostim could be an
130                             Romiplostim is a thrombopoietin receptor agonist that increases platelet
131              Eltrombopag is a small molecule thrombopoietin receptor agonist that might be a new opti
132 RE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (g
133                         Eltrombopag, an oral thrombopoietin receptor agonist, increases platelet coun
134             We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in i
135                                              Thrombopoietin receptor agonists (eltrombopag; romiplost
136 has changed with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options fo
137  efficacy and safety, in particular, for the thrombopoietin receptor agonists and the occurrence of l
138                                              Thrombopoietin receptor agonists are reported to increas
139 ents respond to antithymocyte globulins, and thrombopoietin receptor agonists are under investigation
140                   Tier 1 options (rituximab, thrombopoietin receptor agonists, low-dose corticosteroi
141 templating pregnancy while on treatment with thrombopoietin receptor agonists, rituximab, or mycophen
142   More recently, activating mutations in the thrombopoietin receptor and in JAK2 exon 12 have been id
143                                            A thrombopoietin receptor derivative that brings the proli
144 atic activating mutations in JAK2 and in the thrombopoietin receptor gene (MPL) in most patients with
145 al 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL).
146  a p.Lys39Asn amino acid substitution of the thrombopoietin receptor gene (p = 1.5 x 10(-11)).
147  a chemically induced dimerizer and modified thrombopoietin receptor has now allowed the expansion of
148 mutations of the erythropoietin receptor and thrombopoietin receptor have been identified in familial
149 e discovery of an activating mutation in the thrombopoietin receptor in JAK2-negative myelofibrosis a
150  resultant mice were compared with a Mpl-/- (thrombopoietin receptor knockout) thrombocytopenic murin
151                           Endocytosis of the thrombopoietin receptor Mpl was impaired in Dnm2-null pl
152 e demonstrated that mutant CALR binds to the thrombopoietin receptor MPL, and that the positive elect
153 en OTT-MAL and an activating mutation of the thrombopoietin receptor myeloproliferative leukemia viru
154            miR-28 exerts negative effects on thrombopoietin receptor signaling and platelet formation
155 scribed, somatic, activating mutation in the thrombopoietin receptor that is sensitive to down-stream
156                                 Although the thrombopoietin receptor was discovered in 1991 and throm
157  this idea, the signaling domain of Mpl (the thrombopoietin receptor) was targeted to the plasma memb
158  expression of p21(Cip1), p27(Kip1), and the thrombopoietin receptor, known regulators of HSC self-re
159 nner in 1 of 3 genes: JAK2, CALR, or MPL The thrombopoietin receptor, MPL, is the key cytokine recept
160 tor, the erythropoietin receptor (EpoR), the thrombopoietin receptor, or the granulocyte colony-stimu
161 omerize with several other tagged receptors (thrombopoietin receptor, transforming growth factor beta
162 at from mice lacking c-Mpl (c-Mpl(-/-)), the thrombopoietin receptor.
163 P were randomly assigned to receive the oral thrombopoietin-receptor agonist eltrombopag (30, 50, or
164         Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that stimulates thrombop
165          Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombop
166  immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically signi
167                The effects of eltrombopag, a thrombopoietin-receptor agonist, on platelet function in
168                       Eltrombopag is an oral thrombopoietin-receptor agonist.
169                           PURPOSE OF REVIEW: Thrombopoietin-receptor agonists (TPO-RAs) have been app
170        Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effecti
171  Combining an immunosuppressant therapy with thrombopoietin-receptor agonists may be a good strategy
172 combination of immunosuppressant therapy and thrombopoietin-receptor agonists that lasted for a media
173 er induction with erythropoietin, G-CSF, and thrombopoietin, respectively.
174 forms of the c-Mpl ligand--recombinant human thrombopoietin (rhTPO) and pegylated recombinant human m
175                            Recombinant human thrombopoietin (rhTPO) increases platelets, and the peak
176 les exposed to SB, but not recombinant human thrombopoietin (rhTpo), in liquid suspension culture.
177  to 10 mum ABA does not increase recombinant thrombopoietin (rTpo)-dependent Mk differentiation or pl
178 nd germ-line-activating mutations affect the thrombopoietin signaling axis.
179 karyocytes to the endosteal niche depends on thrombopoietin signaling through the c-MPL receptor on m
180 ressed in hematopoietic cells and suppresses thrombopoietin signaling via its receptor myeloprolifera
181                        In contrast, enhanced thrombopoietin signaling, conferred by enforced expressi
182             Treatment with recombinant human thrombopoietin significantly increased platelet count (m
183 + thrombopoietin) or four cytokines (Flt3L + thrombopoietin + stem cell factor + interleukin 3).
184 oncontact HUBEC cultures and the addition of thrombopoietin, stem cell factor (SCF), and macrophage c
185 /mpl, silencing of TRIB3 increased basal and thrombopoietin-stimulated megakaryocyte antigen expressi
186                                              Thrombopoietin stimulates extracellular signal-related k
187 itro to produce proplatelets, independent of thrombopoietin stimulation, and they responded to stimul
188  itself is tyrosine-phosphorylated following thrombopoietin stimulation.
189 -Mpl, the cellular receptor for the cytokine thrombopoietin, suggest that c-Mpl does not control HSC
190           In mouse models, increased hepatic thrombopoietin synthesis in response to tumor-derived in
191 of platelet-biased HSCs crucially depends on thrombopoietin, the primary extrinsic regulator of plate
192 de, with the cloning and characterization of thrombopoietin, the primary regulator of this process.
193                                 Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and t
194                                              Thrombopoietin therapy can increase platelet counts in h
195 ets collected from healthy donors undergoing thrombopoietin therapy were safe and resulted in signifi
196                      The interaction between thrombopoietin (THPO) and its receptor c-Mpl regulates d
197 the hereditary thrombocytosis induced by the thrombopoietin (THPO) receptor MPL P106L mutant remain u
198                            Expression of the thrombopoietin (THPO) receptor MPL was elevated in leuke
199                                              Thrombopoietin (Thpo) signaling through the c-Mpl recept
200 ne, MPL, a homodimeric receptor activated by thrombopoietin (THPO), is mutated in myeloproliferative
201 ealed that Bcl-xL expression is regulated by thrombopoietin (THPO)/MPL-signaling induced by AE expres
202 ng identified mutations in the gene encoding thrombopoietin (THPO): THPO R99W, homozygous in affected
203 fied a novel homozygous missense mutation in thrombopoietin (THPO, c.112C>T) in both affected sibling
204 granules, and forming PPTs without exogenous thrombopoietin, thus identifying a novel and unexplored
205                     Finally, we administered thrombopoietin to mice beginning 5 days before marrow ra
206                               The binding of thrombopoietin to Mpl activates multiple kinase pathways
207 kt in BaF3/Mpl cells restored the ability of thrombopoietin to promote cell cycling in the presence o
208 g factor, stem cell factor, flt3 ligand, and thrombopoietin, to this SCEPF activity.
209                                              Thrombopoietin (TPO) acting via its receptor, the cellul
210 karyocyte production, signaling initiated by thrombopoietin (TPO) activation of its receptor, myelopr
211  that c-Cbl(-/-) HSCs are hyperresponsive to thrombopoietin (TPO) and display elevated levels of STAT
212               Recently, interactions between thrombopoietin (TPO) and its receptor, the myeloprolifer
213    We investigated the association of plasma thrombopoietin (TPO) and overall survival in 127 patient
214 ulxin, and the cytokine receptor Mpl agonist thrombopoietin (TPO) are able to induce activation of RA
215                                              Thrombopoietin (TPO) attracts much attention as an effec
216     Multiple lines of evidence indicate that thrombopoietin (TPO) contributes to the development of h
217                            Here we show that thrombopoietin (TPO) cooperates with FLT3-L, inducing CD
218 In our previous studies we demonstrated that thrombopoietin (TPO) enhances levels of HOXB4 mRNA in pr
219 differentiated in a medium supplemented with thrombopoietin (TPO) for 18 days.
220 ition, BM from Cib1(-/-) mice, cultured with thrombopoietin (TPO) for 24 hours, produced more highly
221 vels are controlled by circulating levels of thrombopoietin (TPO) functioning to activate megakaryocy
222  etiology of this disease, we identified the thrombopoietin (Tpo) gene as a target of the SMRT-retino
223                                              Thrombopoietin (TPO) has been demonstrated as a crucial
224                                  The role of thrombopoietin (Tpo) in promoting hematopoiesis has been
225                                              Thrombopoietin (Tpo) is a glycoprotein growth factor tha
226                                              Thrombopoietin (TPO) is the major regulator of megakaryo
227                                              Thrombopoietin (Tpo) is the primary cytokine regulating
228                                              Thrombopoietin (TPO) is the primary regulator of platele
229                                 Finally, two thrombopoietin (Tpo) mimetics were approved by the FDA f
230 ets to the AMR induces hepatic expression of thrombopoietin (TPO) mRNA and protein, thereby regulatin
231 pffer cells, ultimately leading to increased thrombopoietin (TPO) production in the liver.
232 L), increased cell surface expression of the thrombopoietin (TPO) receptor (c-MPL) and enhanced proli
233                Here we show that loss of the thrombopoietin (TPO) receptor (MPL) significantly amelio
234 ut not CALRdelex9, specifically activate the thrombopoietin (TPO) receptor (MPL) to induce constituti
235 mbocythemia (ET) with mutations in JAK2, the thrombopoietin (TPO) receptor (MPL), and the calreticuli
236 ing through an abnormal interaction with the thrombopoietin (TPO) receptor (MPL).
237 pression of murine JAK2 V617F and the murine thrombopoietin (Tpo) receptor (TpoR, c-MPL) in hematopoi
238                                          The thrombopoietin (TPO) receptor c-Mpl, like other members
239                                   Mpl is the thrombopoietin (TPO) receptor.
240 on of these cells in the presence of dox and thrombopoietin (TPO) resulted in an exponential (at leas
241 elinexor causes thrombocytopenia by blocking thrombopoietin (TPO) signaling and therefore differentia
242 This pattern is associated with up-regulated thrombopoietin (TPO) signaling through mammalian target
243                                              Thrombopoietin (TPO) stimulates a network of intracellul
244     Multiple lines of evidence indicate that thrombopoietin (TPO) substantially impacts the number of
245 otein that dampens signaling by the cytokine thrombopoietin (Tpo) to limit HSC expansion.
246                                     The term thrombopoietin (TPO) was first coined in 1958 and used t
247                                        Serum thrombopoietin (TPO) was maintained at normal levels in
248 opoietin receptor was discovered in 1991 and thrombopoietin (TPO) was purified in 1994, the developme
249 design, antibody fragments (Fabs) that mimic thrombopoietin (TPO) were created.
250  IL-8, VEGF receptors VEGFR1 and VEGFR2, and thrombopoietin (TPO) were measured in plasma samples of
251                We have previously shown that thrombopoietin (TPO), a critical HSC regulator, ensures
252                                              Thrombopoietin (Tpo), acting through its receptor c-Mpl,
253                                              Thrombopoietin (Tpo), acting through the c-Mpl receptor,
254 in transcription factors, in the response to thrombopoietin (Tpo), and newly described developmentall
255                 Up-regulation of survivin by thrombopoietin (Tpo), Flt3 ligand (FL), and stem cell fa
256 eloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells.
257  using low levels of stem cell factor (SCF), thrombopoietin (TPO), insulin-like growth factor 2 (IGF-
258 2-step differentiation process, regulated by thrombopoietin (TPO), on binding to its cognate receptor
259  some individuals treated with a recombinant thrombopoietin (TPO), pegylated recombinant human megaka
260 ) messenger RNA (mRNA) expression; (3) serum thrombopoietin (Tpo), stem cell factor (SCF), interleuki
261                                              Thrombopoietin (TPO), the c-Mpl ligand, is the primary p
262                                              Thrombopoietin (TPO), the critical regulator of platelet
263                                              Thrombopoietin (TPO), the primary regulator of platelet
264                                              Thrombopoietin (TPO), the primary regulator of platelet
265                                              Thrombopoietin (TPO), the primary regulator of thrombopo
266        We demonstrate that in the absence of thrombopoietin (TPO), tyrosine-unphosphorylated STAT5 (u
267 one marrow endothelial cells (BMECs) promote thrombopoietin (TPO)-independent platelet production.
268 ffect of an Src kinase inhibitor, SU6656, on thrombopoietin (TPO)-induced growth and differentiation.
269                                              Thrombopoietin (Tpo)-induced in vitro expansion of ES ce
270 own Lyn kinase to be a negative regulator of thrombopoietin (TPO)-induced proliferation.
271                                              Thrombopoietin (Tpo)-mediated activation of Lyn kinase,
272 s (HSCs) harboring DNA damage are rescued by thrombopoietin (TPO)-mediated DNA repair.1 It has been r
273 ain HSC homeostasis by positively regulating thrombopoietin (Tpo)-mediated Jak2 signaling.
274               We show that IFN-gamma reduces thrombopoietin (TPO)-mediated phosphorylation of signal
275 tion of miR-193b upon self-renewal promoting thrombopoietin (TPO)-MPL-STAT5 signalling.
276 induction of a luciferase reporter gene in a thrombopoietin (TPO)-responsive cell line resulted in th
277            In this study we demonstrate that thrombopoietin (TPO)-stimulated Src family kinases (SFKs
278 reaction of purified mouse MKs isolated from thrombopoietin (TPO)-treated bone marrow (BM) cultures i
279 ion signals after stimulation by its ligand, thrombopoietin (TPO).
280  adult hematopoietic microenvironment and to thrombopoietin (Tpo).
281 (CpG) demethylation that can be initiated by thrombopoietin (TPO).
282 imary mean of regulating the plasma level of thrombopoietin (TPO).
283 stromal cell derived factor-1a (SDF-1a), and thrombopoietin (TPO).
284 ting factor (GM-CSF), Steel factor (SLF), or thrombopoietin (TPO).
285 factor (SCF) + interleukin 7 (IL-7), or FL + thrombopoietin (Tpo).
286  cloned, and generated recombinant zebrafish thrombopoietin (Tpo).
287                  Soluble Kit-ligand (sKitL), thrombopoietin (TPO, encoded by Thpo) and, to a lesser e
288 mbopoietic growth factors (recombinant human thrombopoietin [TPO] and pegylated recombinant human meg
289 F], insulinlike growth factor-1 [IGF-1], and thrombopoietin [TPO]); cytokines (tumor necrosis factor-
290 structed by either in vivo overexpression of thrombopoietin (TPOhigh mice) or megakaryocyte lineage r
291 e 2 (JAK2) is essential for signaling by the thrombopoietin (TpoR) and erythropoietin (EpoR) receptor
292 oped with the discovery that the recombinant thrombopoietins (TPOs) could enhance platelet production
293 tion of VEGFR-3 increased platelet counts in thrombopoietin-treated mice significantly and modulated
294 giopoietin-like 3 and IGF2, but also SCF and thrombopoietin, two other growth factors important for H
295 d; and the primary regulator of the process, thrombopoietin, was cloned and characterized and therape
296      Tumor-derived interleukin-6 and hepatic thrombopoietin were also linked to thrombocytosis in pat
297         No antibodies against romiplostim or thrombopoietin were detected.
298 tibodies to either romiplostim or endogenous thrombopoietin were seen.
299 ing and have lost the potentiating effect of thrombopoietin (which couples to JAK2) on this pathway.
300  on hepatocytes to enhance the production of thrombopoietin, which in turn interacts with its cognate

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top